China
-
Moscow Center and Beijing University partner to improve early breast cancer detection with AI
Russian experts bring experience in producing medical phantoms-models that mimic human tissues and organs used for equipment calibration and training, while their Chinese counterparts contribute advanced mathematical algorithms for signal processing.
-
Merck invests US$200M upfront in China’s Hengrui cardiovascular therapy
Elevated levels of lipoprotein (a) are linked to a heightened risk of atherosclerotic cardiovascular disease, affecting approximately one in five adults worldwide, potentially leading to severe health problems, including heart attacks and strokes.
-
Novo Nordisk licenses triple agonist UBT251 from United Laboratories for obesity and diabetes
In this agreement, United Biotechnology will receive an upfront payment of US$200 million, with potential milestone payments from Novo Nordisk that could reach up to US$1.8 billion.
-
AstraZeneca invests US$2.5B to expand R&D footprint in China
The new R&D center will prioritize early-stage research and clinical development, enhanced by data science and an AI lab.
-
TaiMed’s HIV therapy shows strong Phase 2a results
The study highlighted the regimen’s effectiveness in maintaining viral suppression, with an impressive 94% of participants keeping their viral RNA levels below 50 copies/mL throughout the 24-week treatment period.
-
-
-
-
-
